Log in to save to my catalogue

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentr...

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentr...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2424143096

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

About this item

Full title

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1547-1557

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.
In this multicentre, phase 3, randomised trial,...

Alternative Titles

Full title

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2424143096

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2424143096

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(20)30230-0

How to access this item